Trial reportClinical oral investigations2017
Effects of enamel matrix derivative on non-surgical management of peri-implant mucositis: a double-blind randomized clinical trial.
Trial report in Clinical oral investigations, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Clinical Outcomes of Enamel Matrix Derivate Used in Surgical and Non-Surgical Treatment of Peri-Implantitis: A Systematic Review of Clinical Studies.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Efficacy of growth factors for the treatment of peri-implant diseases: a systematic review and meta-analysis.Clinical oral investigations · 2020Pooled it
- Three Decades of Enamel Matrix Derivative: From Dental Innovation to Extra-Oral Applications.International journal of dentistry · 2026Review
- Evaluation of Long-Term Outcomes of Enamel Matrix Derivative in the Treatment of Peri-Implant Disease: A Systematic Review and Meta-Analysis.Bioengineering (Basel, Switzerland) · 2025Review
- An Update Regarding the Use of Contemporary Dental Materials in Periodontal Regeneration.Materials (Basel, Switzerland) · 2025Review
- The Effect of Peri-Implant Therapy on the Expression of Th17-Related Cytokines in Patients with Peri-Implant Mucositis and Peri-Implantitis: A Prospective Longitudinal Study.Journal of clinical medicine · 2025Article
- A prospective evaluation of subgingival irrigation with i-PRF following non-surgical treatment of peri-implantitis.Frontiers in dental medicine · 2025Article
- Peri-Implantitis.Dentistry journal · 2024Review
- Local Oxygen-Based Therapy (blueMedicina (Kaunas, Lithuania) · 2024Review
- Novel Flowchart Guiding the Non-Surgical and Surgical Management of Peri-Implant Complications: A Narrative Review.Bioengineering (Basel, Switzerland) · 2024Review
- Enamel Matrix Derivative (EMD) as an Adjunct to Non-surgical Periodontal Therapy: A Systematic Review.Cureus · 2023Review
- Effects of Enamel Matrix Derivative on Cell Spheroids Made of Stem Cells Obtained from the Gingiva on Osteogenic Differentiation.Medicina (Kaunas, Lithuania) · 2023Article
- Enamel Matrix Derivatives for Periodontal Regeneration: Recent Developments and Future Perspectives.Journal of healthcare engineering · 2022Review
- The Applications of Enamel Matrix Derivative in Implant Dentistry: A Narrative Review.Materials (Basel, Switzerland) · 2021Review
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-implant diseases have been recognized as being among the ever-increasing complications related to dental implants. The aim of this study was to evaluate the adjunctive use of enamel matrix derivative (EMD) to mechanical debridement (MD) in patients with these conditions in terms of clinical parameters and cytokine levels of peri-implant crevicular fluid (PICF).
methodsIn the present double-blind clinical trial, 46 patients with peri-implant mucositis (PM) were randomly divided into control and test groups. Two different therapeutic protocols, consisting of non-surgical MD alone (control group) and MD with the application of EMD (test group), were considered for the two groups. Clinical parameters [bleeding on probing (BOP) and probing depth (PD)] and sampling from PICF were carried out before treatment and 3 months postoperatively. The levels of IL-6 and IL-17 cytokines in PICF were evaluated by enzyme-linked immunosorbent (ELISA).
resultsThree-month post-interventional assay revealed significant improvements in BOP and PD in the test group in comparison to the control group (P < 0.0001). Relative to control, IL-6 and IL-17 levels were reduced significantly (p < 0.05) in the test group compared to the control group.
conclusionApplication of EMD can be considered an adjunct to MD in the non-surgical treatment of PM. However, complete recovery was not observed using either treatment approach showing that management of implant-associated disease is still a significant clinical problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.